CD20

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Retrieved on: 
星期一, 十一月 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lymphoma, Ovarian cancer, BCMA, CD20, Edinburgh Cancer Research Centre, Queen Elizabeth Hospital, National Institute for Health and Care Excellence, Brain, Patient, NHL, Wales, Cancer, National Institute, Health care, Cancer Research UK, Innovation, ALL, Lymphoid leukemia, University Hospitals Birmingham NHS Foundation Trust, CAR, Entrepreneurship, CD19, Temozolomide, Healthcare Improvement Scotland, Neoplasm, Prostate cancer, SMC, CTE, Acute lymphoblastic leukemia, Lymphatic system, Antigen, NICE, Drug development, Medicine, Leukemia, Cancer research, MHRA, Therapy, The Queen Elizabeth Hospital, Adelaide, AML, B-cell maturation antigen, Pharmaceutical industry, Vaccine

Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.
  • This designation for our biologic CAR T-cell therapy engager ALETA-001 marks an important step in addressing the high unmet need for patients who relapse or progress following CD19-targeted CAR T-cell therapy for blood cancers, such as lymphoma and leukemia, stated Paul Rennert, Co-Founder, Acting Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.
  • ALETA-001 is an off-the-shelf preclinical biologic program developed to treat and prevent cell therapy relapse of existing CD19-targeted CAR T-cell therapies, termed CAR19 T cells.
  • Aleta Biotherapeutics is an immune-oncology company with a portfolio and platform of novel off-the-shelf biologic CAR T engagers (CTEs) that work in synergy with cell therapies to improve outcomes for patients.

Shattuck Labs Presents Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Disclosure, Company, FC, GLOBE, Cell, BTN3A1, CD20, Poster, Immunotherapy, Autoimmune disease, Lymphoma, NASDAQ, CD47, Antigen, Society, Regulation, Patient, Cancer, B7-H3, Regulation Fair Disclosure, Vaccine, CD40

AUSTIN, TX and DURHAM, NC, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data from the company’s novel GADLEN platform at the 2022 SITC Annual Meeting.

Key Points: 
  • B7-H3 is an antigen that is broadly expressed by many solid tumors, with limited expression in normal tissues.
  • In our preclinical models, our B7-H3 GADLEN directed human gamma delta T cells to selectively kill B7-H3 expressing human tumor cells, including those that expressed very low density of the B7-H3 antigen.
  • Similarly, in our preclinical models, our CD20 GADLEN directed human gamma delta T cells to selectively kill both CD20 expressing tumor cells, and also CD20 expressing healthy B cells.
  • Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.

EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
星期一, 十一月 7, 2022
Constellation, FC, Cyclophosphamide, Adult, Bruise, CD19, Flushing, PFS, Dor, ADCC, Fever, Rituximab, Partnership, CD20, RCHOP, Sheraton New Orleans, ADCP, Food, CST, Final Analysis, ASCT, ASH, Rash, BET, Safety, Lenalidomide, Chills, Blinded, Prednisone, TD, JAK, Gene, Cancer, Pharmacokinetics, PET, ORR, Progression-free survival, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Headache, Lymphoid leukemia, Immunotherapy, Arm, Vincristine, Incyte, Apoptosis, Death, Bleeding, Doxorubicin, GLA, Pharmaceutical industry, Medical imaging, Vaccine, Patient, DLBCL, Infection, Tafasitamab, MorphoSys, Primary myelofibrosis

As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

Key Points: 
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been evaluated or approved by any regulatory authorities.
  • MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.
  • Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose.

Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Retrieved on: 
星期四, 十一月 3, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mantle cell lymphoma, Biotechnology, Risk, Antibody, Modulation, Cell, CAR, CD20, Least, CD3, Relapse, Risk management, Follicular lymphoma, B-cell lymphoma, Annual report, U.S. Securities and Exchange Commission, DOI, Environment, Engelbert Humperdinck (singer), Technology, Lymphoid leukemia, SEC, Cancer, Standard of care, Vaccine, Patient, Genmab

Health Care Resource Utilization and Costs of CAR T Therapy in Patients With Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis.

Key Points: 
  • Health Care Resource Utilization and Costs of CAR T Therapy in Patients With Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis.
  • Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types.
  • To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies.
  • Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

Retrieved on: 
星期四, 十一月 3, 2022
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Patient, Janssen, ORR, Non-Hodgkin lymphoma, Annual report, Cytokine, Private Securities Litigation Reform Act, Therapy, III, Society, CD28, DLBCL, Cancer, IL6, Antibody, Form 10-K, NHL, Cytokine release syndrome, ER, Safety, Neutropenia, Thrombocytopenia, Incidence, CMR, AES, CD20, CD3, ASH, CRS, Cmax, Trial of the century, U.S. Securities and Exchange Commission, Clinical trial, Escalation, Lenalidomide, Forward-looking statement, NASDAQ, Technology, Anemia, Security (finance), Degenerative disease, AE, Follicular lymphoma, Vaccine, Pharmaceutical industry, RD

Xencors first combination study, evaluating plamotamab in combination with tafasitamab plus lenalidomide, is enrolling patients with advanced, aggressive lymphoma.

Key Points: 
  • Xencors first combination study, evaluating plamotamab in combination with tafasitamab plus lenalidomide, is enrolling patients with advanced, aggressive lymphoma.
  • The accepted abstract with data from the study is accessible through the ASH website.
  • At data cut off on July 25, 2022, 36 patients with relapsed or refractory non-Hodgkins lymphoma (NHL) had been enrolled on or before April 1, 2022 and received the RD.
  • Plamotamab is also being evaluated in a Phase 2 study, in combination with tafasitamab plus lenalidomide, in patients with relapsed or refractory diffuse large B-cell lymphoma.

ATCC Announces New Immuno-oncology CAR-T Target Luciferase Reporter Cell Lines to Enable Discovery and Development of Immunotherapies

Retrieved on: 
星期四, 十一月 3, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Public health, Research, Science, Therapy, Industry, Government, CAR, History, CD20, Poster, CD19, China Biologic Products, IO, Lymphatic system, Immunotherapy, CEO, Annual general meeting, Collection, Doctor of Philosophy, Antigen, Society, Drug discovery, HER2, SITC, Society for Immunotherapy of Cancer, Solution, Vaccine, ATCC

ATCC , the worlds premier biological materials management and standards organization, today announced a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies.

Key Points: 
  • ATCC , the worlds premier biological materials management and standards organization, today announced a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies.
  • These new IO tools are comprised of both hematological cancer and solid tumor cell lines that express a luciferase reporter.
  • In addition to providing the most commonly used historical tumor cell lines, ATCC develops genetically engineered cell lines, tumor organoids, reporter cell lines, and drug-resistant cell lines for the global scientific community.
  • At booth 313, they will present the poster, Luciferase reporter cancer cell lines facilitate CAR-T development.

Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Retrieved on: 
星期五, 十月 28, 2022
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Lymph, Cancer, BLA, Lymphoma, European Medicines Agency, DOI, FDA, B-cell lymphoma, Lymphoid leukemia, Cell, MAA, The New England Journal of Medicine, Antibody, Risk management, Nasdaq, Lymphatic system, Environment, Food, Mantle cell lymphoma, ABBV, Patient, Technology, CD20, ORR, Follicular lymphoma, EMA, Biotechnology, Marketing, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Progression-free survival, Annual report, Biologics license application, Risk, CD3, Diffusion, NHL, SEC, DLBCL, AbbVie, NCT, Modulation, NYSE, European Hematology Association, Pharmaceutical industry, Vaccine, Wood drying, Lancet, Genmab

Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration.

Key Points: 
  • Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration.
  • The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
  • Large B-cell lymphoma (LBCL) is a fast-growing type of non-Hodgkins lymphoma (NHL), a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell.
  • The trial was designed to evaluate subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-NHL, including LBCL and DLBCL.

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Retrieved on: 
星期三, 十月 26, 2022
Myelodysplastic syndrome, LAMP1, Warsaw Stock Exchange, Hematology, Șaeș, Lymphatic system, DLBCL, MTA, Merck, Rituximab, ADCC, Acute myeloid leukemia, Neoplasm, Patient, EORTC, Culture, PRMT5, Symposium, GLOBE, NK, AES, DLT, Therapy, WSE, Knowledge, MTAP, CD20, Galápagos Islands, Mouse, Pharmaceutical industry, Vaccine

RVU120 monotherapy continues to be safe, well-tolerated and the dose escalation has now progressed to a dose of 175mg.

Key Points: 
  • RVU120 monotherapy continues to be safe, well-tolerated and the dose escalation has now progressed to a dose of 175mg.
  • Additionally, we presented data from our preclinical studies showing that RVU120 enhances the therapeutic potential of ADCC-promoting drugs in-vivo and in-vitro.
  • Dr. Nogai continued, We also presented preclinical data with our proprietary MTA-cooperative PRMT5 inhibitors that selectively target MTAP deficiency which occurs in 10-15% of all tumors.
  • Ryvu Therapeutics has signed multiple partnering and licensing deals with global companies, including Merck, Menarini Group, Galapagos and Exelixis.

Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System

Retrieved on: 
星期二, 十月 4, 2022
Cancer, Achievement, CSO, Lymphatic system, Toxic epidermal necrolysis, Risk, Technology, Nasdaq, Private Securities Litigation Reform Act, Engineering, CD20, COVID-19, Annual report, Bristol Myers Squibb, U.S. Securities and Exchange Commission, BMY, Therapy, Safety, Cell, NYSE, Epitope, Security (finance), Forward-looking statement, Rituximab, GLOBE, CAR, Pharmaceutical industry, Vaccine

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into an agreement with Bristol Myers Squibb (NYSE: BMY). The agreement grants Bristol Myers Squibb access to incorporate Autolus’ proprietary RQR8 safety switch into an initial set of selected cell therapy programs on a target-by-target basis for the treatment of cancer, with an option for Bristol Myers Squibb to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs.

Key Points: 
  • The agreement grants Bristol Myers Squibb access to incorporate Autolus proprietary RQR8 safety switch into an initial set of selected cell therapy programs on a target-by-target basis for the treatment of cancer, with an option for Bristol Myers Squibb to incorporate the RQR8 safety switch in additional cell therapy programs beyond the initial set of selected programs.
  • Autolus proprietary RQR8 switch works by administration with the widely available and approved pharmaceutical antibody, rituximab.
  • In addition, Autolus would be entitled to receive royalties on net sales of all Bristol Myers Squibb cell therapy products that incorporate the RQR8 safety switch.
  • We look forward to partnering with Bristol Myers Squibb to bring the potential utility of our proprietary safety switch to their programs.

Shattuck Labs Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
星期四, 八月 11, 2022
Disclosure, CD19, Trial of the century, GLOBE, R, Regulation Fair Disclosure, SEC, Cancer, Clinical trial, Toxicity, Investment, TP53, Research, Journal, Annual report, HNSCC, Patient, Monocyte, Autoimmune disease, Enrollment, ARC, Regulation, Lymphoma, Radiation, CSCC, CD47, Safety, Squamous cell carcinoma, Ovarian cancer, Conference, Pharmacokinetics, CD20, Associated, PD-1, Incidence, OX40, PD-L1, AML, Neoplasm, Event, COVID-19, Myelocyte, Anemia, Head, TIGIT, The O.C., Azacitidine, Safe harbor, NK, Research and development, Company, TNF, NASDAQ, Private Securities Litigation Reform Act, Alanine transaminase, Administration, Pharmaceutical industry, Vaccine, Medical imaging, CD80, CD40, Skin

AUSTIN, TX and DURHAM, NC, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended June 30, 2022 and provided recent business highlights.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended June 30, 2022 and provided recent business highlights.
  • Top-line data from the Phase 1 trial are anticipated in the second half of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended June 30, 2022 were $23.0 million, as compared to $14.9 million for the quarter ended June 30, 2021.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended June 30, 2022 were $4.8 million, as compared to $5.4 million for the quarter ended June 30, 2021.